News
Allon Therapeutics, the pharmaceutical company behind the drug Davunetide have announced further progress in the development of a treatment for Progressive Supranuclear Palsy.
Allon Therapeutics Inc. said that its shareholders have approved the terms of the $10 million brokered private placement equity offering to support the finacing of the next stages of the drug's development.
Davunetide is proceeding in a clinical trial for the treatment of progressive supranuclear palsy (PSP) with the U.S. Food and Drug Administration (FDA).
The trial is expected to complete patient dosing and release top-line data by late 2012.
To view the details of the Phase 2/3 trial of Davunetide visit AllonTherapeutics.com or for more information contact the on .
Tagged as: east midlands, local, north east, north west, northern ireland, professionals, research, scotland, south central, south east, south west, west midlands
Published by Helen Porter on June 21st 2012